WntResearch strengthens the management team by appointing a new CEO
To focus entirely on WntResearch's clinical development, CEO Nils Brünner has requested to continue his work in the company as Chief Medical Officer instead of CEO. To replace Nils Brünner the company has appointed Henrik Lawaetz as new CEO from January 1, 2016.WntResearch recently completed a Phase 1 clinical trial with its first drug candidate, Foxy-5. The company is about to embark on an intensive clinical development phase when shortly starting up a Phase 1b study, while continuing to plan for the subsequent Phase 2 study. With the high intensity of work right now, the current CEO Nils